117 related articles for article (PubMed ID: 20592359)
1. Multiplicity of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC) patients treated with tyrosine kinase inhibitors.
Benesova L; Minarik M; Jancarikova D; Belsanova B; Pesek M
Anticancer Res; 2010 May; 30(5):1667-71. PubMed ID: 20592359
[TBL] [Abstract][Full Text] [Related]
2. Dominance of EGFR and insignificant KRAS mutations in prediction of tyrosine-kinase therapy for NSCLC patients stratified by tumor subtype and smoking status.
Pesek M; Benesova L; Belsanova B; Mukensnabl P; Bruha F; Minarik M
Anticancer Res; 2009 Jul; 29(7):2767-73. PubMed ID: 19596959
[TBL] [Abstract][Full Text] [Related]
3. Potential clinical significance of a plasma-based KRAS mutation analysis in patients with advanced non-small cell lung cancer.
Wang S; An T; Wang J; Zhao J; Wang Z; Zhuo M; Bai H; Yang L; Zhang Y; Wang X; Duan J; Wang Y; Guo Q; Wu M
Clin Cancer Res; 2010 Feb; 16(4):1324-30. PubMed ID: 20145159
[TBL] [Abstract][Full Text] [Related]
4. Reversed mutation rates of KRAS and EGFR genes in adenocarcinoma of the lung in Taiwan and their implications.
Wu CC; Hsu HY; Liu HP; Chang JW; Chen YT; Hsieh WY; Hsieh JJ; Hsieh MS; Chen YR; Huang SF
Cancer; 2008 Dec; 113(11):3199-208. PubMed ID: 18932251
[TBL] [Abstract][Full Text] [Related]
5. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer.
Chou TY; Chiu CH; Li LH; Hsiao CY; Tzen CY; Chang KT; Chen YM; Perng RP; Tsai SF; Tsai CM
Clin Cancer Res; 2005 May; 11(10):3750-7. PubMed ID: 15897572
[TBL] [Abstract][Full Text] [Related]
6. EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients.
Bae NC; Chae MH; Lee MH; Kim KM; Lee EB; Kim CH; Park TI; Han SB; Jheon S; Jung TH; Park JY
Cancer Genet Cytogenet; 2007 Mar; 173(2):107-13. PubMed ID: 17321325
[TBL] [Abstract][Full Text] [Related]
7. Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors.
Bonomi PD; Buckingham L; Coon J
Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4606-12. PubMed ID: 17671150
[TBL] [Abstract][Full Text] [Related]
8. Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history.
Mounawar M; Mukeria A; Le Calvez F; Hung RJ; Renard H; Cortot A; Bollart C; Zaridze D; Brennan P; Boffetta P; Brambilla E; Hainaut P
Cancer Res; 2007 Jun; 67(12):5667-72. PubMed ID: 17575133
[TBL] [Abstract][Full Text] [Related]
9. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.
Kosaka T; Yatabe Y; Endoh H; Kuwano H; Takahashi T; Mitsudomi T
Cancer Res; 2004 Dec; 64(24):8919-23. PubMed ID: 15604253
[TBL] [Abstract][Full Text] [Related]
10. Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features.
Tam IY; Chung LP; Suen WS; Wang E; Wong MC; Ho KK; Lam WK; Chiu SW; Girard L; Minna JD; Gazdar AF; Wong MP
Clin Cancer Res; 2006 Mar; 12(5):1647-53. PubMed ID: 16533793
[TBL] [Abstract][Full Text] [Related]
11. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
Jänne PA; Johnson BE
Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4416s-4420s. PubMed ID: 16857820
[TBL] [Abstract][Full Text] [Related]
12. Exclusive mutation in epidermal growth factor receptor gene, HER-2, and KRAS, and synchronous methylation of nonsmall cell lung cancer.
Suzuki M; Shigematsu H; Iizasa T; Hiroshima K; Nakatani Y; Minna JD; Gazdar AF; Fujisawa T
Cancer; 2006 May; 106(10):2200-7. PubMed ID: 16598760
[TBL] [Abstract][Full Text] [Related]
13. Abnormalities of epidermal growth factor receptor in lung squamous-cell carcinomas, adenosquamous carcinomas, and large-cell carcinomas: tyrosine kinase domain mutations are not rare in tumors with an adenocarcinoma component.
Ohtsuka K; Ohnishi H; Fujiwara M; Kishino T; Matsushima S; Furuyashiki G; Takei H; Koshiishi Y; Goya T; Watanabe T
Cancer; 2007 Feb; 109(4):741-50. PubMed ID: 17238183
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of tyrosine kinase inhibitors in routine clinical practice: epidermal growth factor mutations and their implications.
Ovcaricek T; Cufer T; Kern I; Sodja E; Sadikov A
J Cancer Res Ther; 2013; 9(2):261-6. PubMed ID: 23771370
[TBL] [Abstract][Full Text] [Related]
15. The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Fiala O; Pesek M; Finek J; Benesova L; Belsanova B; Minarik M
Cancer Genet; 2013; 206(1-2):26-31. PubMed ID: 23313110
[TBL] [Abstract][Full Text] [Related]
16. Detection and comparison of EGFR mutations in matched tumor tissues, cell blocks, pleural effusions, and sera from patients with NSCLC with malignant pleural effusion, by PNA clamping and direct sequencing.
Yeo CD; Kim JW; Kim KH; Ha JH; Rhee CK; Kim SJ; Kim YK; Park CK; Lee SH; Park MS; Yim HW
Lung Cancer; 2013 Aug; 81(2):207-12. PubMed ID: 23726527
[TBL] [Abstract][Full Text] [Related]
17. [Mutation status of epidermal growth factor receptor and KRAS gene in non-small cell lung cancers at Xuanwei regions of Yunnan Province].
Yang CS; Pan XY; Feng Q; Wang YY; Xu WM; Jiang T; Wang L; Yang JL; Wang L
Zhonghua Bing Li Xue Za Zhi; 2016 Apr; 45(4):226-30. PubMed ID: 27033384
[TBL] [Abstract][Full Text] [Related]
18. NSCLC Patients Harbouring Rare or Complex EGFR Mutations Are More Often Smokers and Might Not Benefit from First-Line Tyrosine Kinase Inhibitor Therapy.
Kauffmann-Guerrero D; Huber RM; Reu S; Tufman A; Mertsch P; Syunyaeva Z; Jung A; Kahnert K
Respiration; 2018; 95(3):169-176. PubMed ID: 29190621
[TBL] [Abstract][Full Text] [Related]
19. Routine EGFR and KRAS Mutation analysis using COLD-PCR in non-small cell lung cancer.
Pennycuick A; Simpson T; Crawley D; Lal R; Santis G; Cane P; Tobal K; Spicer J
Int J Clin Pract; 2012 Aug; 66(8):748-752. PubMed ID: 22805266
[TBL] [Abstract][Full Text] [Related]
20. Identification of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas.
Okayama H; Kohno T; Ishii Y; Shimada Y; Shiraishi K; Iwakawa R; Furuta K; Tsuta K; Shibata T; Yamamoto S; Watanabe S; Sakamoto H; Kumamoto K; Takenoshita S; Gotoh N; Mizuno H; Sarai A; Kawano S; Yamaguchi R; Miyano S; Yokota J
Cancer Res; 2012 Jan; 72(1):100-11. PubMed ID: 22080568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
